| COR |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$4.41 vs. cons $4.35 |
MEDIUM |
| COR |
Report |
Revenue |
IN-LINE |
pred ~$84.20B vs. cons $84.43B |
MEDIUM |
| COR |
Report |
U.S. Healthcare Solutions OI |
BEAT |
pred ~$955M vs. cons $940M |
MEDIUM |
| COR |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$17.65-$17.90 vs. cons $17.79 |
MEDIUM |
| COR |
Guide |
FY2026 revenue growth |
UNCHANGED |
guide ~4%-6% vs. cons $337.01B |
MEDIUM |
| COR |
Guide |
FY2026 U.S. Healthcare Solutions OI growth |
UNCHANGED |
guide ~14%-16% vs. cons $3.77B |
MEDIUM |
| COR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| COR |
Return |
5-day cumulative residual |
-3.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY guide leaves no estimate catalyst |
LOW |